Cite

HARVARD Citation

    Garralda, E. et al. (n.d.). Dose escalation study of OMO-103, a first in class Pan-MYC-Inhibitor in patients (pts) with advanced solid tumors. European journal of cancer. pp. S5-S6. [Online]. 
  
Back to record